



Research Article

Volume 22 Issue 4 - November 2022
DOI: 10.19080/CTOIJ.2022.22.556095

Cancer Ther Oncol Int J

Copyright © All rights are reserved by Dr. Murat Beyzadeoglu

Assessment of Target Definition for Extramedullary Soft Tissue Plasmacytoma: Use of Multimodality Imaging for Improved Targeting Accuracy



Murat Beyzadeoglu*, Selcuk Demiral, Ferrat Dincoglan and Omer Sager

Department of Radiation Oncology; University of Health Sciences, Gulhane Medical Faculty, Turkey

Submission: October 11, 2022; Published: November 10, 2022

*Corresponding author: Dr. Murat Beyzadeoglu, University of Health Sciences, Gulhane Medical Faculty, Department of Radiation Oncology, Gn. Tevfik Saglam Cad. 06018, Etilik, Kecioren Ankara, Turkey

Abstract

Objective: Extramedullary soft tissue plasmacytoma is a relatively rare type of plasma cell neoplasms mostly occurring in the head and neck region and mucosal area of the upper aerodigestive passages. Radiation therapy (RT) may be utilized for management of extraosseous soft tissue plasmacytomas. Improved target definition may be considered as a highly important component of current sophisticated RT approaches. While the most common practice includes the utilization of Computed Tomography (CT) simulation for acquisition of RT planning images, incorporation of other imaging modalities such as Magnetic Resonance Imaging (MRI) may add to the accuracy of target definition. In this original research article, we assess target definition for extramedullary soft tissue plasmacytoma.

Materials and Methods: The patients who have been referred to Department of Radiation Oncology at Gulhane Medical Faculty, University of Health Sciences for radiotherapeutic management of extramedullary soft tissue plasmacytomas were assessed for target definition based on CT only or fused CT-MRI.

Results: Comparative analysis has revealed that utilization of fused CT-MRI based target definition has been identical with ground truth target volume definition for assessed patients with extramedullary soft tissue plasmacytoma.

Conclusion: CT may serve as a preferable method for imaging and dose calculation purposes. However, integration of other imaging modalities may contribute to optimization of target definition for improved targeting accuracy. Our results support the utility of multimodality imaging for precise radiotherapeutic management of extramedullary soft tissue plasmacytomas. Clearly, future studies are needed to shed light on this critical issue.

Keywords: Extramedullary soft tissue plasmacytoma; Radiation therapy (RT); Magnetic Resonance Imaging (MRI)

Introduction

Extramedullary soft tissue plasmacytoma is a relatively rare type of plasma cell neoplasms mostly occurring in the head and neck region and mucosal area of the upper aerodigestive passages [1-4]. To establish the diagnosis of solitary plasmacytoma, a histological verification of clonal plasma cells at a single site is needed. Also, there should be no bone marrow involvement, no clonal plasmacytosis, no bony involvement, no anemia, no hypercalcemia or renal impairment [2-4]. Solitary plasmacytomas may present with single bony lesions referred to as "medullary" or as soft tissue lesions mostly within the mucosal area of upper

aerodigestive passages. Radiation therapy (RT) may be utilized for management of extraosseous soft tissue plasmacytomas [5]. Advances in patient management has been reflected by improved therapeutic outcomes, and quality of life issues and normal tissue sparing have been critical considerations for RT. Integration of contemporary therapeutic concepts and technologies such as molecular imaging methods, automatic segmentation techniques, Image Guided RT (IGRT), Intensity Modulated RT (IMRT), stereotactic RT, and adaptive RT (ART) approaches have considerably contributed to radiotherapeutic management [6-

45]. Nevertheless, improved target definition may be considered as a highly important component of current sophisticated RT approaches. While the most common practice includes the utilization of Computed Tomography (CT) simulation for acquisition of RT planning images, incorporation of other imaging modalities such as Magnetic Resonance Imaging (MRI) may add to the accuracy of target definition as addressed in several studies [46-84]. Herein, we assess target definition for extramedullary soft tissue plasmacytoma with this original research article.

Materials and Methods

The patients who have been referred to Department of Radiation Oncology at Gulhane Medical Faculty, University of Health Sciences for radiotherapeutic management of extramedullary soft tissue plasmacytomas were assessed for target definition based on CT only or fused CT-MRI. A comparative analysis was undertaken for evaluation of target definition based on CT simulation images only or by incorporation of MRI. The main outcome measure of the study was to investigate the utility of multimodality imaging for target definition, however, contouring of critical organs, interobserver and intraobserver variations were also assessed. The ground truth target volume has been used for comparative analysis and for comparison purposes, and it has been defined by attending physicians following meticulous assessment of all imaging and relevant data with detailed colleague peer review and consensus. Decision making process for optimal patient management has involved multidisciplinary input from experts on surgical oncology, radiation oncology, medical oncology and hematology. Individualized assessment included consideration of patient, disease, and treatment related characteristics. Patient age, prior treatments, symptomatology, lesion size, performance status, lesion localization and association with surrounding normal tissues, expected results of offered treatments, patient preferences and logistical issues were all considered in decision making.

A Linear Accelerator (LINAC) with the capability of sophisticated IGRT techniques has been utilized for irradiation. Following rigid immobilization of the patients, planning CT images have been acquired at CT simulator for RT planning. Thereafter, acquired RT planning images were sent to the contouring workstation via the network. Target volumes and critical structures were outlined on these images and structure sets were generated for patients. Either CT simulation images only or fused CT-MR images have been used for comparative assessment and analysis.

Results

This original research article has been designed to assess the utility of multimodality imaging with integration of MRI for target definition in a selected group of patients who were referred for irradiation of extramedullary soft tissue plasmacytoma. Treatment of patients was carried out in Radiation Oncology

Department of Gulhane Medical Faculty at University of Health Sciences, Ankara. Before management with RT, all patients have been assessed individually by multidisciplinary input from relevant disciplines of surgical oncology, radiation oncology, medical oncology and hematology. Briefly, a comparative evaluation has been performed for target and critical organ definition by use of either CT only imaging or by fused CT-MRI to investigate the utility of this contemporary approach. Precise RT planning process included consideration of lesion sizes, location and association with normal tissues in close vicinity. Radiation physicists with considerable expertise on their subject have been involved in RT planning procedures with consideration of reports by American Association of Physicists in Medicine (AAPM) and International Commission on Radiation Units and Measurements (ICRU). Optimized RT planning process has included utmost consideration of electron density, tissue heterogeneity, CT number and HU values in CT images. Prioritized objective of RT planning has been to maintain optimal encompassing of the target volume with minimal exposure of critical structures. Comparative analysis by use of the ground truth target volume as the reference has revealed that utilization of fused CT-MRI based target definition has been identical with ground truth target volume definition for assessed patients with extramedullary soft tissue plasmacytoma.

Discussion

Extramedullary soft tissue plasmacytoma constitutes a rare type of plasma cell neoplasms which mostly occur in the head and neck region and mucosal area of the upper aerodigestive passages [1-4]. A histological verification of clonal plasma cells at a single site is required for establishing the diagnosis of solitary plasmacytoma. Additionally, there should be no bone marrow involvement, no clonal plasmacytosis, no bony involvement, no anemia, no hypercalcemia or renal impairment [2-4]. Solitary plasmacytomas could present with single bony lesions referred to as "medullary" or as soft tissue lesions typically within the mucosal area of upper aerodigestive passages. RT might be used for treatment of extraosseous soft tissue plasmacytomas [5]. Improvements in technology and treatment strategies have translated into optimized treatment results, hence quality of life issues and normal tissue sparing have recently been more critical aspects of radiotherapeutic management. Incorporation of state of the art technologies and evolutionary treatment concepts including automatic segmentation techniques, IGRT, molecular imaging methods, IMRT, stereotactic RT, and ART strategies critically improved management [6-45]. As a matter of fact, optimal target determination could be considered as a critical and indispensable component of contemporary sophisticated irradiation strategies. For the time being, most common practice includes the use of CT simulation for acquisition of RT planning images. CT may serve as a preferable method for imaging and dose calculation purposes. However, integration of other imaging modalities may contribute to optimization of target definition

for improved targeting accuracy [46-84]. To conclude, our results support the utility of multimodality imaging for precise radiotherapeutic management of extramedullary soft tissue plasmacytomas. Clearly, future studies are needed to shed light on this critical issue.

Conflict of Interest

There are no conflicts of interest and no acknowledgements.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. *CA Cancer J Clin* 72(1): 7-33.
2. Rosinol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, et al. (2021) Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *Br J Haematol* 194(3): 496-507.
3. Breen DP, Freeman CL, De Silva RN, Derakhshani S, Stevens J (2017) Soft tissue plasmacytomas in multiple myeloma. *Lancet* 390(10107): 2083.
4. Zuo Z, Tang Y, Bi CF, Zhang WY, Zhao S, et al. (2011) Extramedullary (extramedullary) plasmacytomas: a clinicopathologic and immunophenotypic study of 32 Chinese cases. *Diagn Pathol* 6: 123.
5. Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, et al. (2018) Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys* 101(4): 794-808.
6. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2022) Concise review of radiosurgery for contemporary management of pilocytic astrocytomas in children and adults. *World J Exp Med* 12(3): 36-43.
7. Gamsiz H, Sager O, Uysal B, Dincoglan F, Demiral S, et al. (2022) Active breathing control guided stereotactic body ablative radiotherapy for management of liver metastases from colorectal cancer. *Acta Gastroenterol Belg* 85(3): 1-7.
8. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2022) Optimal timing of thoracic irradiation for limited stage small cell lung cancer: Current evidence and future prospects. *World J Clin Oncol* 13(2): 116-124.
9. Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, et al. (2021) Evaluation of breathing-adapted radiation therapy for right-sided early stage breast cancer patients. *Indian J Cancer* 58(2): 195-200.
10. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2021) Omission of Radiation Therapy (RT) for Metaplastic Breast Cancer (MBC): A Review Article. *International Journal of Research Studies in Medical and Health Sciences* 6(1): 10-15.
11. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2021) Concise review of stereotactic irradiation for pediatric glial neoplasms: Current concepts and future directions. *World J Methodol* 11(3): 61-74.
12. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2020) Adaptive radiation therapy of breast cancer by repeated imaging during irradiation. *World J Radiol* 12(5): 68-75.
13. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Gamsiz H, et al. (2020) Multimodality management of cavernous sinus meningiomas with less extensive surgery followed by subsequent irradiation: Implications for an improved toxicity profile. *J Surg Surgical Res* 6: 056-061.
14. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, Uysal B, et al. (2020) Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated Stereotactic Radiotherapy (FSRT) for Vestibular Schwannoma (VS). *J Surg Surgical Res* 159(6): 062-066.
15. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Uysal B, et al. (2020) A Concise Review of Irradiation for Temporal Bone Chemodectomas (TBC). *Arch Otolaryngol Rhinol* 6: 016-020.
16. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-D-Glucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective. *Curr Radiopharm* 12(1): 4-10.
17. Dincoglan F, Sager O, Demiral S, Gamsiz H, Uysal B, et al. (2019) Fractionated stereotactic radiosurgery for locally recurrent brain metastases after failed stereotactic radiosurgery. *Indian J Cancer* 56(2): 151-156.
18. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Breathing adapted radiation therapy for leukemia relapse in the breast: A case report. *World J Clin Oncol* 10(11): 369-374.
19. Dincoglan F, Sager O, Uysal B, Demiral S, Gamsiz H, et al. (2019) Evaluation of hypofractionated stereotactic radiotherapy (HFSRT) to the resection cavity after surgical resection of brain metastases: A single center experience. *Indian J Cancer* 56(3): 202-206.
20. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2018) Evaluation of adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancer patients having clinically evident seroma. *Jpn J Radiol* 36(6): 401-406.
21. Demiral S, Dincoglan F, Sager O, Uysal B, Gamsiz H, et al. (2018) Contemporary Management of Meningiomas with Radiosurgery. *Int J Radiol Imaging Technol* 80: 187-190.
22. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2017) Splenic Irradiation: A Concise Review of the Literature. *J App Hem Bl Tran* 1: 101.
23. Dincoglan F, Sager O, Demiral S, Uysal B, Gamsiz H, et al. (2017) Radiosurgery for recurrent glioblastoma: A review article. *Neurol Disord Therap* 1: 1-5.
24. Demiral S, Dincoglan F, Sager O, Gamsiz H, Uysal B, et al. (2016) Hypofractionated stereotactic radiotherapy (HFSRT) for WHO grade I anterior clinoid meningiomas (ACM). *Jpn J Radiol* 34(11): 730-737.
25. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Gamsiz H, et al. (2015) Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. *Tumori* 101(2): 179-184.
26. Gamsiz H, Beyzadeoglu M, Sager O, Demiral S, Dincoglan F, et al. (2015) Evaluation of stereotactic body radiation therapy in the management of adrenal metastases from non-small cell lung cancer. *Tumori* 101(1): 98-103.
27. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2015) Adaptive splenic radiotherapy for symptomatic splenomegaly management in myeloproliferative disorders. *Tumori* 101(1): 84-90.
28. Sager O, Dincoglan F, Beyzadeoglu M (2015) Stereotactic radiosurgery of glomus jugulare tumors: Current concepts, recent advances and future perspectives. *CNS Oncol* 4(2): 105-114.
29. Sager O, Beyzadeoglu M, Dincoglan F, Uysal B, Gamsiz H, et al. (2014) Evaluation of linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) for cerebral cavernous malformations: A 15-year single-center experience. *Ann Saudi Med* 34(1): 54-58.
30. Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, et al. (2014) Evaluation of Linear Accelerator (Linac)-Based Stereotactic Radiosurgery (Srs) for the Treatment of Craniopharyngiomas. *UHOD-Uluslararası Hematoloji Onkoloji Dergisi* 24(2): 123-129.

31. Sager O, Beyzadeoglu M, Dincoglan F, Gamsiz H, Demiral S, et al. (2014) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of glomus jugulare tumors. *Tumori* 100(2): 184-188.
32. Ozsavas EE, Telatar Z, Dirican B, Sager O, Beyzadeoglu M (2014) Automatic segmentation of anatomical structures from CT scans of thorax for RTP. *Comput Math Methods Med* 2014: 472890.
33. Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, et al. (2014) Evaluation of linear accelerator (linac)-based stereotactic radiosurgery (srs) for the treatment of craniopharyngiomas. *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi* 24: 123-129.
34. Gamsiz H, Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, et al. (2014) Management of pulmonary oligometastases by stereotactic body radiotherapy. *Tumori* 100(2): 179-183.
35. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2014) Management of patients with ≥ 4 brain metastases using stereotactic radiosurgery boost after whole brain irradiation. *Tumori* 100(3): 302-306.
36. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2013) Management of vestibular schwannomas with linear accelerator-based stereotactic radiosurgery: a single center experience. *Tumori* 99(5): 617-622.
37. Dincoglan F, Beyzadeoglu M, Sager O, Uysal B, Demiral S, et al. (2013) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of meningiomas: A single center experience. *J BUON* 18(3): 717-722.
38. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Kahya YE, et al. (2013) Dosimetric evaluation of critical organs at risk in mastectomized left-sided breast cancer radiotherapy using breath-hold technique. *Tumori* 99(1): 76-82.
39. Demiral S, Beyzadeoglu M, Uysal B, Oysul K, Kahya YE, et al. (2013) Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer. *Neoplasma* 60(3): 322-327.
40. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) Evaluation of active breathing control-moderate deep inspiration breath-hold in definitive non-small cell lung cancer radiotherapy. *Neoplasma* 59(3): 333-340.
41. Sager O, Dincoglan F, Gamsiz H, Demiral S, Uysal B, et al. (2012) Evaluation of the impact of integrated [18 F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging on staging and radiotherapy treatment volume definition of non-small cell lung cancer. *Gulhane Med J* 54: 220-227.
42. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) The Role of Active Breathing Control-Moderate Deep Inspiration Breath-Hold (ABC-mDIBH) Usage in non-Mastectomized Left-sided Breast Cancer Radiotherapy: A Dosimetric Evaluation *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi* 22(3): 147-155.
43. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2012) Stereotactic radiosurgery for intracranial tumors: A single center experience. *Gulhane Med J* 54: 190-198.
44. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Sirin S et al. (2012) Image-guided positioning in intracranial non-invasive stereotactic radiosurgery for the treatment of brain metastasis. *Tumori* 98(5): 630-635.
45. Sirin S, Oysul K, Surenkoc S, Sager O, Dincoglan F, et al. (2011) Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: A single center experience. *Vojnosanit Pregl* 68(11): 961-966.
46. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2022) Assessment of Target Volume Definition for Precise Radiotherapeutic Management of Locally Recurrent Biliary Tract Cancers: An Original Research Article. *Biomed J Sci & Tech Res* 46(1): 37054-37059.
47. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2022) Radiation Therapy (RT) Target Volume Determination for Locally Advanced Pyriform Sinus Carcinoma: An Original Research Article Revisiting the Role of Multimodality Imaging. *Biomed J Sci & Tech Res* 45(1): 36155-36160.
48. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2022) Improved Target Volume Definition for Radiotherapeutic Management of Parotid Gland Cancers by use of Multimodality Imaging: An Original Article. *Canc Therapy & Oncol Int J* 21(3): 556062.
49. Beyzadeoglu M, Sager O, Demiral S, Dincoglan F (2022) Reappraisal of multimodality imaging for improved Radiation Therapy (RT) target volume determination of recurrent Oral Squamous Cell Carcinoma (OSCC): An original article. *J Surg Surgical Res* 8: 004-008.
50. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2022) Multimodality imaging based treatment volume definition for recurrent Rhabdomyosarcomas of the head and neck region: An original article. *J Surg Surgical Res* 8(2): 013-018.
51. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2022) Appraisal of Target Definition for Management of Paraspinal Ewing Tumors with Modern Radiation Therapy (RT): An Original Article. *Biomed J Sci & Tech Res* 44(4): 35691-35696.
52. Beyzadeoglu M, Sager O, Demiral S, Dincoglan F (2022) Assessment of Target Volume Definition for Contemporary Radiotherapeutic Management of Retroperitoneal Sarcoma: An Original Article. *Biomed J Sci & Tech Res* 44(5): 35883-35887.
53. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2021) Assessment of Multimodality Imaging for Target Definition of Intracranial Chondrosarcomas. *Canc Therapy Oncol Int J* 18(2): 001-005.
54. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Impact of Multimodality Imaging to Improve Radiation Therapy (RT) Target Volume Definition for Malignant Peripheral Nerve Sheath Tumor (MPNST). *Biomed J Sci Tech Res* 34(3): 26734-26738.
55. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2021) Multimodality Imaging Based Treatment Volume Definition for Reirradiation of Recurrent Small Cell Lung Cancer (SCLC). *Arch Can Res* 9(1): 1-5.
56. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2021) Radiation Therapy (RT) Target Volume Definition for Peripheral Primitive Neuroectodermal Tumor (PPNET) by Use of Multimodality Imaging: An Original Article. *Biomed J Sci & Tech Res* 34(4): 26970-26974.
57. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2021) Evaluation of Target Definition for Management of Myxoid Liposarcoma (MLS) with Neoadjuvant Radiation Therapy (RT). *Biomed J Sci Tech Res* 33(5): 26171-26174.
58. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Radiation Therapy (RT) target determination for irradiation of bone metastases with soft tissue component: Impact of multimodality imaging. *J Surg Surgical Res* 7(1): 042-046.
59. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Evaluation of Changes in Tumor Volume Following Upfront Chemotherapy for Locally Advanced Non Small Cell Lung Cancer (NSCLC). *Glob J Cancer Ther* 7(1): 031-034.
60. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2021) Assessment of posterior fossa target definition by multimodality imaging for patients with medulloblastoma. *J Surg Surgical Res* 7(1): 037-041.
61. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Assessment of the role of multimodality imaging for treatment volume definition of intracranial ependymal tumors: An original article. *Glob J Cancer Ther* 7(1): 043-045.

62. Beyzadeoglu M, Dincoglan F, Demiral S, Sager O (2020) Target Volume Determination for Precise Radiation Therapy (RT) of Central Neurocytoma: An Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5(3): 29-34.
63. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2020) Utility of Multimodality Imaging Based Target Volume Definition for Radiosurgery of Trigeminal Neuralgia: An Original Article. *Biomed J Sci & Tech Res* 26(2): 19728-19732.
64. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Assessment of Target Volume Definition for Radiosurgery of Atypical Meningiomas with Multimodality Imaging. *Journal of Hematology and Oncology Research* 3(4): 14-21.
65. Dincoglan F, Beyzadeoglu M, Demiral S, Sager O (2020) Assessment of Treatment Volume Definition for Irradiation of Spinal Ependymomas: an Original Article. *ARC Journal of Cancer Science* 6(1): 1-6.
66. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2020) Target Volume Definition for Stereotactic Radiosurgery (SRS) Of Cerebral Cavernous Malformations (CCMs). *Canc Therapy & Oncol Int J* 15: 555917.
67. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Treatment Volume Determination for Irradiation of Recurrent Nasopharyngeal Carcinoma with Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6(2): 18-23.
68. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Assessment of Target Volume Definition for Irradiation of Hemangiopericytomas: An Original Article. *Canc Therapy & Oncol Int J* 17(2): 555959.
69. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Treatment Volume Determination for Irradiation of chordoma: an Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5 (10): 3-8.
70. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2020) Multimodality Imaging Based Target Definition of Cervical Lymph Nodes in Precise Limited Field Radiation Therapy (Lfrt) for Nodular Lymphocyte Predominant Hodgkin Lymphoma (Nlphl). *ARC Journal of Cancer Science* 6(2): 06-11.
71. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Radiosurgery Treatment Volume Determination for Brain Lymphomas with and without Incorporation of Multimodality Imaging. *Journal of Medical Pharmaceutical and Allied Sciences* 9(1): 2398-2404.
72. Beyzadeoglu M, Dincoglan F, Sager O, Demiral S (2020) Determination of Radiosurgery Treatment Volume for Intracranial Germ Cell Tumors (GCTS). *Asian Journal of Pharmacy, Nursing and Medical Sciences* 8(3): 18-23.
73. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2020) Target Definition of orbital Embryonal Rhabdomyosarcoma (Rms) by Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6(2): 12-17.
74. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Target Volume Determination for Irradiation of Pilocytic Astrocytomas: An Original Article. *ARC Journal of Cancer Science* 6(1): 1-5.
75. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Evaluation of Radiosurgery Target Volume Definition for Tectal Gliomas with Incorporation of Magnetic Resonance Imaging (MRI): An Original Article. *Biomedical Journal of Scientific & Technical Research (BJSTR)* 27(2): 20543-20547.
76. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S (2019) Evaluation of Target Definition for Stereotactic Reirradiation of Recurrent Glioblastoma. *Arch Can Res* 7: 3.
77. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Evaluation of the Impact of Magnetic Resonance Imaging (MRI) on Gross Tumor Volume (GTV) Definition for Radiation Treatment Planning (RTP) of Inoperable High Grade Gliomas (HGGs). *Concepts in Magnetic Resonance Part A* 2019: 4282754.
78. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Utility of Magnetic Resonance Imaging (Imaging) in Target Volume Definition for Radiosurgery of Acoustic Neuromas. *Int J Cancer Clin Res* 6(3): 119.
79. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of Computed Tomography (CT) And Magnetic Resonance Imaging (MRI) Based Radiosurgery Treatment Planning for Pituitary Adenomas. *Canc Therapy & Oncol Int J* 13(2): 555857.
80. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Multimodality Imaging for Radiosurgical Management of Arteriovenous Malformations. *Asian Journal of Pharmacy, Nursing and Medical Sciences* 7(1): 7-12.
81. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2019) Evaluation of Radiosurgery Target Volume Determination for Meningiomas Based on Computed Tomography (CT) And Magnetic Resonance Imaging (MRI). *Cancer Sci Res Open Access* 5(2): 1-4.
82. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of target definition based on Multimodality imaging for radiosurgical Management of glomus jugulare tumors (GJTs). *Canc Therapy & Oncol Int J* 15(2): 555909.
83. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Incorporation of Multimodality Imaging in Radiosurgery Planning for Craniopharyngiomas: An Original Article. *SAJ Cancer Sci* 6: 103.
84. Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, et al. (2018) Evaluation of Target Volume Determination for Single Session Stereotactic Radiosurgery (SRS) of Brain Metastases. *Canc Therapy & Oncol Int J* 12(5): 555848.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/CTOIJ.2022.22.556095](https://doi.org/10.19080/CTOIJ.2022.22.556095)

**Your next submission with Juniper Publishers
will reach you the below assets**

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission

<https://juniperpublishers.com/online-submission.php>